Amylyx Pharmaceuticals (AMLX) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 103.3% versus a loss of 7.0%. Xenon Pharmaceuticals is the larger company by market cap ($3.53 billion vs $3.44 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | XENE |
|---|---|---|
| Share price | $27.43 | $36.41 |
| Market cap | $3.44B | $3.53B |
| 1-day change | -2.18% | -0.44% |
| YTD return | +127.07% | -18.76% |
| 1-year return | +103.34% | -7.02% |
| 5-year return | — | +8.17% |
| EPS (TTM) | $-1.41 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $7.50M |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-144.74M | $-345.91M |
| Operating margin | — | -4974.27% |
| Net margin | — | -4612.13% |
| 52-week high | $41.14 | $72.66 |
| 52-week low | $10.83 | $35.75 |
| Distance from 52-week high | -33.33% | -49.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +54.43% | +101.51% |
| Average volume | 2.33M | 1.47M |
| Shares outstanding | 125.51M | 96.84M |
| Employees | 136 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed XENE by 110.4 percentage points over the past year.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
AMLX vs XENE FAQ
Which is bigger, Amylyx Pharmaceuticals or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.53B compared with $3.44B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or XENE?
AMLX returned +103.34% over the past 12 months, compared with -7.02% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.